Take a look at our previous reports:

Q1 Report 2022

Contingencies and commitments

Contractual obligations and commitments

We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.

On 31 March 2022, we had outstanding obligations for purchase commitments, which become due as follows:

(thousands of €)

Total

Less than
1 year

1 – 3 years

3 – 5 years

More than 5 years

Purchase commitments

456,078

269,252

134,626

49,385

2,814

In addition to the table above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €342.2 million at 31 March 2022 for which we have direct purchase commitments of €242.0 million at 31 March 2022 reflected in the table above.

Contingent liabilities and assets

We refer to our Annual Report 2021 for a description of our contingent liabilities and assets.

Filgotinib
Formerly known as GLPG0634, commercial name is Jyseleca. Small molecule preferential JAK1 inhibitor, approved in RA and UC in European Union, Great Britain, and Japan. Filgotinib is partnered with Gilead. Filgotinib currently is in Phase 3 trials in CD, and in a Phase 4 trial in RA